PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant

卷:12

Review

关键词: VERSUS-HOST-DISEASE;    CONSENSUS DEVELOPMENT PROJECT;    BONE-MARROW-TRANSPLANTATION;    NATURAL-KILLER-CELLS;    ANTIGEN-PRESENTING CELLS;    MURINE CHRONIC GVHD;    PROGRAMMED DEATH-1;    GRAFT-REJECTION;    CLINICAL-TRIALS;    DENDRITIC CELLS;   

DOI  :  10.3390/cells12121609

来源: SCIE

【 摘 要 】

Over the past decade, Programmed Death-Ligand 1 (PD-L1) has emerged as a prominent target for cancer immunotherapies. However, its potential as an immunosuppressive therapy has been limited. In this review, we present the immunological basis of graft rejection and graft-versus-host disease (GVHD), followed by a summary of biologically relevant molecular interactions of both PD-L1 and Programmed Cell Death Protein 1 (PD-1). Finally, we present a translational perspective on how PD-L1 can interrupt alloreactive-driven processes to increase immune tolerance. Unlike most current therapies that block PD-L1 and/or its interaction with PD-1, this review focuses on how upregulation or reversed sequestration of this ligand may reduce autoimmunity, ameliorate GVHD, and enhance graft survival following organ transplant.